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1 INTRODUCTION 
 
1.1 Endothelial barrier function 
Endothelial cells (EC) form a single cell layer of the inner surface of all blood 
vessels. This single cell layer, called endothelium, acts as a selective barrier for water, 
solutes, macromolecules and cells and controls the movement of all components 
between the tissue and streaming blood. Under physiological conditions endothelial cells 
are not only involved in barrier function but also in regulation of a variety of processes 
like angiogenesis, hemostasis, and blood flow (Stevens et al., 2001). Failure of 
endothelial barrier function may occur under pathophysiological conditions, like 
inflammation, sepsis or ischemia-reperfusion, which may cause local or systemic edema 
formation leading to acute life-threatening complications (Mehta and Malik, 2006; Michel 
and Curry, 1999). The mechanisms by which the endothelial barrier is maintained under 
physiological conditions as well as those processes leading to barrier failure are topics 
of many studies aiming to identify new strategies to protect the endothelial barrier. 
Recently, it was shown that ATP, released from endothelial cells in response to 
reperfusion, can protect endothelial barrier against reperfusion-induced failure (Gündüz 
et al., 2006). The ATP release mechanism involved in this process, however, is 
unknown. The present study aimed to analyze this release mechanism in a model of 
cultured endothelial cells from porcine aorta. 
1.2 Disturbance of endothelial barrier function 
Endothelial cells are among the first targets of noxious processes induced during 
inflammation, ischemia-reperfusion, traumatic tissue injury or coagulation. Therefore, the 
failure of barrier function is one of the earliest signs of cell injury causing extravasation 
of plasma components and cells of the bloodstream and finally leading to organ 
dysfunction. Disturbance of endothelial cells which takes place in response to 
reperfusion of the ischemic heart causes obstruction of microvessels and prevents 
restoration of blood flow of the previously ischemic myocardium. This so called “no-
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reflow phenomenon” (Kloner et al., 1974), resulting from endothelial ischemia-
reperfusion injury, is a critical determinant for the myocardial infarction. During 
reperfusion, barrier failure due to endothelial cell injury may be induced by many 
exogenous factors involving leucocyte or platelet-interaction with endothelial cells, 
production of reactive oxygen species (ROS) released from activated leucocytes or 
myocytes or the complement system (Eltzschig and Collard, 2004). However, barrier 
failure may also be triggered by endogenous endothelial mechanisms. As shown in 
cultured endothelial cells as well as in isolated saline-perfused hearts (Gündüz et al., 
2006), the principle endothelial effector mechanisms involved in the acute increase in 
permeability during reperfusion are: loss of cell-cell or cell-matrix adhesion, disassembly 
of the endothelial cytoskeleton and activation of the contractile machinery. These 
mechanisms cause retraction of endothelial cells and formation of intercellular gaps 
(Gündüz et al., 2006; Schäfer et al., 2003). Ischemia-reperfusion may also cause 
shedding of the endothelial glycocalyx (Rehm et al., 2007), which represents an 
important determinant of physiological endothelial barrier (Becker et al., 2010).  
1.3 Release of ATP from cardiovascular cells 
Forrest and Williams (1977) are among the first who reported that ATP is 
released from isolated cardiomyocytes under normoxic conditions and that the release 
was enhanced when the cells were exposed to hypoxia. Today, it is well established that 
all cells of the cardiovascular system release ATP into the interstitial space or, in case of 
endothelial cells, also directly into the vascular lumen (Burnstock, 2002; Clarke, 2009; 
Faigle et al., 2008; Gomes et al., 2005). This release is enhanced due to shear stress 
(Bodin and Burnstock, 2001; Yegutkin et al., 2000), oxidative or osmotic stress (Taylor et 
al, 1998; Schwiebert et al, 2002), and during blood coagulation (Gordon et al., 1986), 
inflammation (Bodin and Burnstock, 1998), or ischemia-reperfusion (Bergfeld and 
Forrester, 1992; Clemens and Forrester, 1981). After being released, ATP binds to cell 
surface receptors like P2Y and P2X and may regulate the vascular tone (Burnstock, 
2006). P2Y receptors may act via Ca
+2-dependent eNOS activation, which causes nitric 
oxide production, while P2X receptors may act as ATP sensors (Khakh and North, 
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2006). Sometimes, ATP undergoes degradation leading to the formation of adenosine 
(ADO), which causes arterial vasodilation via A2-adenosine receptors (Burnstock, 2002). 
Extracellular ADO and ATP have been shown to be protective during hypoxia or 
ischemia (Baxter, 2002; Linden, 2001). In addition, ATP has also been found to be 
released in response to a hypoxic or an ischemic stimulus, and the increase in 
extracellular ATP can help in stabilization of endothelial barrier function via purinergic 
signaling (Noll et al., 2000; Gündüz et al., 2006; Eltzschig et al., 2006). ATP reduces the 
permeability of microvascular coronary endothelial cells. It not only stabilizes the barrier 
but also reduces the thrombin-induced loss of barrier function (Gündüz et al., 2003; Noll 
et al., 2000; Klingenberg et al., 2004). If ATP degradation is prevented, it reduces 
myocardial edema formation in response of reperfusion (Gündüz et al., 2006).  
Although it is well established that vascular cells release ATP, the molecular and 
signaling mechanisms involved are still not known. Various possible mechanisms may 
come into consideration including volume-regulated anion channels (VRACs), vesicular 
exocytosis, ATP binding cassette (ABC) transporters, plasmalemmal voltage-dependent 
anion channels, P2X7-receptor channels, as well as connexin or pannexin hemichannels 
(Goodenough and Paul, 2003; Fiagle et al., 2008; Leybaert et al., 2003; Stout et al., 
2002; D’hondt et al., 2009).  
1.4 Connexin 
1.4.1 Connexins and connexons 
Endothelial cells form a variety of cell-cell contacts such as tight junctions (Rubin, 
1992), adhesion junctions (Rubin, 1992), and gap junctions (Goodenough and Paul, 
2003; Ebihara, 2003). Gap junctions (Gj) form connections between the cytoplasm of 
two adjacent cells. Each cell contributes half of the intercellular channel, also known as 
hemichannel or connexon. Each hemichannel is composed of six protein subunits 
termed connexins (Cx). One hemichannel in the plasma membrane docks to another 
hemichannel of the adjacent cell and forms a complete gap junctional channel. Ions and 
small molecules with a mass of up to 1 kDa can diffuse through gap junctional channels 
allowing electrical and metabolic coupling of cells (Goodenough and Paul, 2003).  
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A connexon may be homomeric (contains single type of connexins) or 
heteromeric (contains multiple connexins). In addition, neighbouring cells could 
contribute homomeric or heteromeric connexons also called homotypic or heterotypic 
intercellular channels. Due to this fact, large varieties of Cx channels are available with 
different properties of permeability, selectivity, conductance, and gating (Bukauskas et 
al., 2002; Elfgang et al., 1995; Goldberg et al., 2004; Grikscheit et al., 2008; Rackauskas 
et al., 2007).  
There are 20 members in Cx gene family in the mouse and 21 members in the 
human genome. The structure of connexins is highly conserved among the Cx family 
members. It consists of four transmembrane domains. One intracellular loop and two 
extracellular loops with six conserved cysteine residues are involved in Gj formation 
(Söhl and Willecke, 2004). The C-terminal end is in the cytosol and varies in length, 
causing the different molecular masses of Cx. This C-terminal end has been shown to 
be phosphorylated by many kinases regulating the open propability of Cx, while the N-
terminal end, also located in the cytosplasm, is not (Lampe and Lau, 2000). The C-
terminal domain is usually involved in controlling different functions by providing the site 
of protein-protein interactions (Söhl and Willecke, 2004). 
Generally, the Gj formation starts either within the endoplasmic reticulum or in the 
trans-golgi network, where the formation of newly synthesized Cx into connexons takes 
place. The exception is Cx26, which seems to bypass the trans-golgi network (Evans et 
al., 2006). After being synthesized inside the endoplasmic reticulum, the connexons are 
transported via vesicles towards the plasma membrane, where they get inserted. 
However, to form the Gj, the connexons move towards the Gj plaque and dock with Gj 
plaques of adjacent cells to form complete Gj channel (Ebihara, 2003). 
Cx are short-lived with half-life of about 1-3 h, as they are regularly degraded. 
The degradation process could be via one of the following routes: (1) via proteosomes 
including endoplasmic reticulum degradation, (2) by lysosomes prior to reaching the 
plasma membrane or (3) or, if already integrated into Gj, Cx plaques are degraded by 
lysosomes after endocytotic internalization. Degradation process involves ubiquitination 
and phosphorylation (Berthoud et al., 2004). 
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Connexons have also been detected at the cell surfaces, forming so called Cx 
hemichannels that are not part of intercellular Gj. Generally these hemichannels remain 
in a closed state on the surface of most cells. Cx activation might be a common 
response to metabolic inhibition (Goodenough and Paul, 2009). However, the exact 
signaling mechanism involved in connexin hemichannel opening is still unclear. 
1.4.2 Role of connexins in the cardiovascular system 
The vascular wall consists of layered smooth muscle cells and the endothelium 
both of which are connected by Gj (Little et al., 1995). Depending upon the cell type and 
the compartment, four types of Cx have been detected in the vascular wall, i.e., Cx37, 
Cx40, Cx43, and Cx45 (Haefliger et al., 2004). In endothelial cells, major forms of Cx are 
Cx37, Cx40 and Cx43. The distribution suggests that Cx37 and Cx43 are involved in 
more diverse processes than Cx40 (Sáez et al., 2003). 
Studies have been undertaken to elucidate the function of cardiovascular Cx. The 
importance of Cx43 has been explained with the experiments performed on Cx43 null 
mice. These animals survive until birth. At the time of birth, they have a beating heart but 
they die shortly after birth due to obstruction of the right ventricle (Sáez et al., 2003). 
Heterozygous Cx43 mice (Cx43 +/-), however, have slow epicardial conduction in the 
ventricle (Guerrero et al., 1997; Thomas et al., 1998).  
1.4.3 Regulation of connexins 
Cx are regulated by interacting with other cellular proteins. Usually this regulation 
is mediated by phosphorylation and has been shown by incorporation of 32P. 12 of the 
21 serines (Lampe and Lau, 2004) and 2 of the tyrosines of Cx43 are phosphorylated by 
several different kinases (Solan and Lampe, 2009; Lampe and Lau, 2004). 
With the exception of Cx36 and Cx56, which can be also phosphorylated in the 
cytoplasmic loop region, Cx are mainly phosphorylated in the C-terminal domain (Solan 
and Lampe, 2009). There is no evidence of phosphorylation of the N-terminal region 
(Lampe and Lau, 2004). As Cx26 is the shortest Cx among all, this protein does not 
show phosphorylation at all (Traub et al., 1989). 
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The most commonly expressed Cx is Cx43, as its presence has been detected in 
34 tissues and 46 cell types (Laird, 2006). Cx43 is most probably the best analyzed Cx 
in regard to phosphorylation and function. No serine residue has been detected in the 
cytoplasmic loop of Cx43. Cx43 can be phosphorylated by the activation of several 
different kinases such as protein kinase A (PKA), protein kinase C (PKC), mitogen-
activated protein kinase (MAPK), and pp60src kinase (Src) (Solan and Lampe, 2009). 
Previous studies have shown that PKA causes an increase of Gj synthesis as 
well as electrical coupling of cardiac cells (Imanaga et al., 2004). Maneuvers inducing an 
upregulation of cAMP also cause an increase in Cx43 phosphorylation and intercellular 
communication (TenBroek et al., 2001). These effects could be suppressed by PKA 
inhibitors (Matsumura et al., 2006). Such evidence suggests that the effect of cAMP on 
the Gj function is mediated by increase in phosphorylation of Cx43 in a PKA dependent 
manner (Imanaga et al., 2004). Furthermore, it was suggested that PKA-mediated 
phosphorylation of Cx43 enhances open probability of Gj, intercellular coupling 
(Imanaga et al., 2004) and either a delay in the degradation or acceleration of the 
synthesis of connexin protein (Matsumura et al., 2006).  
In contrast, it has been shown that activation of PKC or MAPK results in a 
phosphorylation of the Cx43 and reduction of open probability of Cx43 hemichannels 
(Warn-Cramer et al., 1998; Kim et al., 1999). Increase in Cx43 phosphorylation is 
associated with an increase in reduced Gj communication, and reduced electrical 
coupling (Moreno, 2005). On the other hand, Cx43 hemichannel permeability increases 
with phosphatase treatment (Kim et al., 1999). 
1.5 Connexins and ATP release 
Cx as hemichannels are known to be involved in the paracrine communication as 
they facilitate trafficking of substances across cell membranes into the interstitial space. 
One of them also includes the release of ATP (Clarke et al., 2009).  
As mentioned earlier, ATP is released from many different cell types. For some 
cell types, this ATP release can be blocked by inhibitors of Cx, ABC-protein family 
members or nucleoside transporters (Wang et al., 2005). Regardingly, involvement of 
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Cx43 on ATP release was shown in neuronal astrocytes (Stout et al., 2002), PMN 
(polymorpho nuclear cells) (Eltzschig et al., 2008), cardiomyocytes as well as bovine 
corneal and human microvascular endothelial cells (Clarke et al., 2009; Faigle et al., 
2008; Gomes et al., 2005) during ischemic conditions and shear stress. 
1.6 Connexin channel openers 
During myocardial infarction, disruption of Gj as well as reduction in Cx43 
expression has been identified as critical determinants in genesis of arrhythmia. 
Therefore, the availability of agents like the hexapeptide AAP10, a so called 
antiarrhythmic peptide, which enhances the formation of gap junctions and intercellular 
coupling, represents a promising therapeutic option to prevent arrhythmia (Müller et al., 
1997). The concept to enhance cell coupling by a pharmacological agent was further 
supported by ZP123, which is a much more stable chemical analogue of the AAP10 
(Salameh and Dhein, 2005). ZP123 has similar effects as AAP10. It increases the 
intercellular communication, promotes electrical coupling, and attenuates gap junctional 
closure (Clarke et al., 2006). Although AAP10 is less stable than ZP123, it can be used 
to study the effect of connexin-mediated cell-cell communication. AAP10 enhances the 
metabolic coupling and the expression level of Cx43 via a PKC-dependent pathway 
(Easton et al., 2009). 
Alendronate, a 250 Da synthetic molecule, belongs to a group of 
bisphosphonates. It is used for the treatment of several bone diseases and has anti-
apoptotic effects on osteocytes and osteoblasts (Plotkin et al. 1999). Further studies 
revealed that alendronate may act as an opener of Cx43 hemichannels, which is 
assumed to induce a signaling pathway of cell survival, involving activation of Src and 
ERK kinase in response to an interaction with the C-terminal domain of Cx43 (Plotkin et 
al. 2002). The exact mechanism by which alendronate causes the opening of Cx43 as 
well as the activation of the survival cascade is still unknown.  
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1.7 Pannexins 
Previously, it was thought that Gjs are formed only from Cxs in vertebrates. 
However, this conception was changed when another family of Gj proteins, called 
innexins (Inxs), was identified in invertebrates (Phelan, 2005). Orthologous of Inxs 
discovered in vertebrates are named as pannexins (Panxs) (Panchin et al., 2000). 
Although Cxs and Inxs/Panxs are formed independent of each other and show little 
sequence homology, they show many common features such as the ability to form Gj 
and facilitate intercellular communication. Hemichannels for Cx, Inx, or Panx are called 
connexons, innexons, or pannexons, respectively (D'hondt et al., 2009). 
As mentioned earlier, Cxs have a short half-life of 3 hours depending on the cell 
type (Beardslee et al., 1998). On the other hand, Panxs have a half-life of more than 6 h, 
indicating that Panxs synthesis and expression might be regulated differently (Penuela 
et al., 2007). Like Cxs, Panxs can also be activated by different stimuli like shear stress, 
ATP or other agonists (D'hondt et al., 2009). 
Cx channels are known to show high open probability when extracellular Ca+2 
levels are reduced (Thimm et al., 2005). In contrast, Panxs are unaffected by 
extracellular Ca+2 levels (Bruzzone et al., 2005). On the other hand, open probability is 
enhanced when intracellular Ca+2 level is increased (Locovei et al., 2006). It has been 
observed that Panxs channels open in response to agonist-induced increase in cytosolic 
Ca+2 concentration (Locovei et al., 2006). Recently, it has been shown that Panx1 
interacts with P2X7 receptor and may form a P2X7-Panxz1 complex (Kim and Kang, 
2011). Release of ATP via Panxs has recently been observed in erythrocytes in 
response to lower oxygen tension (Sridharan et al., 2010) causing the activation of 
cAMP-dependent PKA pathway (Adderley.et al., 2010). However, the detailed 
mechanism of this ATP release is still unclear (Sridharan et al., 2010). 
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1.8 Aims and objectives of the study 
In the present study, the hypothesis was tested whether vascular endothelial cells 
do release endogenous ATP during reoxygenation and keep barrier failure at bay. 
Previous studies in endothelial cells have demonstrated that ATP, when exogeneously 
applied during reperfusion, protects the endothelial barrier against reperfusion injury. 
The study was performed using an established model of cultured monolayers of porcine 
aortic endothelial cells (PAEC). The following questions were addressed. 
 What is the mechanism involved in reoxygenation-induced ATP release in 
endothelial cells? 
 Is the reoxygenation-induced ATP release Cx43 dependent? 
 What role are Panxs, Cx37 and Cx40 playing in this ATP release? 
 What is the signaling mechanism underlying the reoxygenation-induced ATP 
release? 
 What is the role of Cx43 phosphorylation and how is this mechanism modulated by 
PKA? 
 Do Cx channel openers enhance the protective effect of ATP release from 
endothelial cells? 
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2 METHODS 
2.1 Preparation of endothelial cells 
Isolation and cultivation of endothelial cells from porcine aortas 
Porcine aortic endothelial cells (PAEC) were freshly isolated from porcine aortas of 
approx. 20 cm of length isolated at the slaughter house and transported in 0.9% (wt/vol) 
NaCl solution. Afterwards the aortas were cleaned from the outside by cutting off fat, 
loose tissue, and lymphatic nodes. After cleaning, the aorta was opened cutting along 
the intercoastal arteries, fixed on an aluminum foil covered styropor board and rinsed 
with 0.9% (wt/vol) NaCl solution. Subsequently the upper layer of endothelial cells was 
scraped with a scalpel and transferred into 40 ml of pre-warmed M199 medium. 
Harvested cells were pelleted by centrifugation for 10 min at 260 x g at room 
temperature, the medium was removed and the cells were resuspended in 40 ml fresh 
cell culture medium. Subsequently the cell suspension was spread onto primary culture 
dishes (approx. 3-4 aortas / dish) containing 10 ml of cell culture medium with 5% 
(vol/vol) penicillin/streptomycin. After 3 hours of incubation at 37 °C and 5% CO2 cells 
were extensively washed with HEPES/Tyrode’s buffer (HBS) to remove non-adherent 
cells and cell debris. Afterwards adherent endothelial cells were incubated in 15-20 ml of 
cell culture medium containing 5% (vol/vol) penicillin/streptomycin at 37 °C and 5% CO2. 
After 24 hours the cell culture medium was changed to medium containing 2% (vol/vol) 
penicillin/streptomycin and incubation was continued at 37 °C and 5% CO2. 
M199 / CO2- Medium: (pH 7.4) 
Medium 199 / Earl’s Salts  9.62 g/l 
HEPES    15 mM 
NaHCO3    24 mM 
Carbogen    Perfused approx. 1 hour. 
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Cell culture medium: 
M199 / CO2- medium    x ml 
NCS (vol/vol)      20% 
Penicillin/streptomycin (100 lU/ml, 100 µg/ml) 2% (vol/vol) 
 
HEPES/Tyrode’s buffer (HBS): (pH 7.4) 
NaCl      125 mM 
KCL      2.6 mM 
KH2PO4     1.2 mM 
MgSO4     1.2 mM 
HEPES     25 mM 
 
2.2 Subcultivation of endothelial cells 
Confluent monolayers of endothelial cell cultures were trypsinized 7 to 10 days after 
isolation. Cells were washed with HBSS (KH2PO4 0.44 mM, KCL 5.37 mM, Na2HPO4 
0.34 mM, NaCl 136.89 mM, and D-Glucose 5.55 mM) and subsequently incubated with 
3 ml of trypsin/EDTA solution (composition in mM: 137 NaCl, 2.7 KCL, 1.5 KH2PO4, 8.0 
Na2HPO4, pH 7.4, 0.05% (wt/vol) trypsin and 0.02% (wt/vol) EDTA). Detached cells 
were collected into cell culture medium and cells were seeded at a density of 2.2x104 
cells/cm2 on 35 mm dishes according to the experiment being performed. For 
immunostaining and confocal microscopy cells were seeded on 2.5 cm glass coverslips. 
2.3 Application of pharmacological compounds 
Stock solutions were prepared immediately before use in basal medium or DMSO. 
Appropriate volumes of these solutions were added to the cells yielding final solvent 
concentrations ≤ 0.1% (vol/vol). The same final concentration of DMSO was also 
included in all respective control experiments. 
 
 
                      Methods 
 Page 12 
 
2.4 Experimental protocol for hypoxia 
Sub-confluent monolayers of endothelial cells (80-90% confluent) were equilibrated on 
heating plates at 37 oC for 40 min after changing the medium with HEPES buffer (NaCl 
125 mM; KCl 2.6 mM; MgCl2  1.2 mM; KH2PO4 1.2 mM; HEPES 25 mM; pH 7.4; 1.3 mM 
CaCl2 was added just before use). Afterwards 40 min of hypoxia was produced in an air 
tight incubation chamber by exposing cells to a continuous stream of humidified N2 gas 
(Po2 approximately 10 mmHg), while the normoxic controls were exposed to humidified 
air (Po2 = 140 mmHg). Afterwards cells were reoxygenated for 15 min by opening the 
airtight incubation chamber. 
Hypoxia medium 
HEPES buffer    x ml 
CaCl2      1.3 mM 
 
A       B 
 
 
 
 
 
 
Photograh 1: (A) Photographs showing the air tight hypoxic incubation chambers 
through which a continuous stream of N2 gas is passed. The chambers on the right side 
are exposed to humidified air as a normoxic control. (B). Close view of chambers 
showing the cell culture dishes exposed to N2 gas. 
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2.5 Transfection of endothelial cells 
In order to reduce endogenous Cx43 content, endothelial cells were transfected with 
Cx43-specific siRNA duplex and transfection reagent jetSI-ENDO 24 h prior to 
experiments according to manufacturer’s instruction. Specific siRNA against porcine 
Cx43 was designed and produced by Eurogenetec (Köln, Germany) according to 
accession no: AY382593. The three different antisense sequences tested and used are 
as follows: 
Cx43.1: 5’-AGAGAGGAAACAGTCCACC-3’. 
Cx43.2: 5’-ATGAAGATGATGAAGATGG-3’. 
Cx43.3: 5’-AACAGACACAAATATGATC-3’. 
Non-specific control siRNA duplex from two different companies was used as a negative 
control. Most effective Cx43 silencing was achieved with concentrations of 100nM of 
duplex siRNA for 24 h. 
2.6 Detection of ATP release 
The amount of the ATP released into the cell culture medium of endothelial monolayers 
was determined with the luciferin-luciferase assay as described by Gündüz et al. (2006) 
with minor modifications. Cells in 35 mm dishes were exposed to 40 min of hypoxia (Po2 
< 10 mmHg) or control normoxia (Po2 = 140 mmHg) in gas tight chambers, respectively. 
Medium of endothelial monolayer was collected very carefully without touching the cells 
at the end of hypoxia and at different time points of reoxygenation. Three samples of 80 
µl each were mixed with 80 µl of ATP luciferin-luciferase assay reagent in an eppendorf 
tube, vortexed and then immediately placed into a TD 20/20 Luminometer (Turner 
Designs) and measured for 10 s after a delay of 1 s. All assays were performed at room 
temperature. As control all pharmacological substances were tested with ATP standard 
performed in each individual experiment.  
2.7 Detection of LDH release 
The activity of cytoplasmic marker enzyme lactate dehydrogenase (LDH) was assayed 
by a commercial detection kit (CytoTox-One, Promega, Mannheim, Germany). LDH was 
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assayed in the supernatant of endothelial monolayers during reperfusion according to 
manufacturer’s instructions. In short, confluent PAEC monolayers were exposed to 
hypoxia followed by reoxygenation, subsequently 100 µl of the substrate mixture from 
the kit were added to 100 µl of the collected protein-free supernatant. After an incubation 
of 30 min the absorbance was measured at 490 nm. In positive control samples, PAECs 
were treated with 9 % Triton X-100 to access the maximal release of LDH. 
2.8 Protein analysis 
2.8.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Resolving gel buffer: Tris/HCl; pH 8.8   120 mM 
Stacking gel buffer: Tris/HCl; pH 6.8   120 mM 
2.8.2 Sample preparation 
Endothelial cells were lysed in 200 μl SDS sample buffer (250 mM Tris/HCl; pH 6.8, 20 
% (vol/vol) glycerol, 4 % (wt/vol) SDS, 1 % (vol/vol) mercaptoethanol, 0.001 % (wt/vol) 
bromphenol blue, and 10 mM DTT (added freshly before use). Subsequently, 50 IU/ml 
benzonase in 2 mM MgCl2 was added and the lysate was collected in a 1.5 ml 
Eppendorf tube. Samples were denatured for 10 minutes at 65 °C and used immediately 
or stored at –20 °C. 
 
10 x Gel running buffer 
Tris     250 mM 
Glycine    2.0 M 
SDS (wt/vol)    10 % 
 
Stacking gel 6% 
Acrylamide 40% (wt/vol)    3.8 ml 
Bisacrylamide 2% (wt/vol)    2 ml 
Stacking buffer pH 6.8    6 ml 
Demineralized water    17.5 ml 
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SDS 10% (wt/vol)     250 µl 
APS 10% (wt/vol)     200 µl 
TEMED      20 µl 
 
Resolving gel 12.5% 
Acrylamide 40% (wt/vol)    12.7 ml 
Bisacrylamise 2% (wt/vol)    7 ml 
Resolving buffer pH 6.8    9.5 ml 
Demineralized water    9.8 ml 
SDS 10% (wt/vol)     0.4 ml 
APS 10%       0.4 ml 
TEMED      30 µl 
 
Procedure. After cleaning the glass plates and spacers with water and ethanol, the gel 
apparatus was assembled and the resolving gel solution was poured (app. 10 cm 
height), and layered with water. The gel was let to polymerize for 3-4 hours or overnight 
at room temperature. 
The layer of water was removed, the stacking gel solution was poured on top of the 
resolving gel, the comb was inserted and the stacking gel was let to polymerize for 1 
hour at room temperature. After removing the comb 1X running gel buffer was added to 
the chamber and the wells were washed with a syringe. Protein samples were loaded 
into the wells and the gel was run overnight at 85 volts. The run was stopped before 36 
kD prestained marker protein reached approximately the end of the gel 1cm before 
running out. 
 
2.9 Electroblotting and immunodetection of proteins (Western Blot) 
Proteins separated by SDS-PAGE were transferred onto a nitrocellulose membrane by 
semi-dry blotting. Afterwards specific proteins were immunodetected using specific 
antibodies. 
 
                      Methods 
 Page 16 
 
Materials and solutions 
 Nitrocellulose transfer membrane, cut to the same dimensions as the gel. 
 Six pieces of Whatman® 3 MM filter paper, cut to the same dimensions as 
the gel. 
 Blotting chamber. 
 Blotting buffer : 25 mM Tris/HCl; 150 mM glycine pH 8.3, 10 % (vol/vol) methanol 
 Millipore water 
 
Procedure. The blotting chamber was assembled as follows: Three sheets of filter 
paper (Whatman® 3MM) are soaked in blotting buffer were placed in the centre of the 
graphite anode of the blotting chamber. On top of these sheets, equilibrated 
nitrocellulose membrane was placed. The SDS gel (devoid of stacking gel) was layered 
on top of the nitrocellulose membrane, avoiding air bubbles. Three sheets of filter paper, 
presoaked in blotting buffer, were again placed on top of the gel followed by the graphite 
cathode of the blotting chamber. Transfer was achieved by application of 0.8-0.9 mA/cm2 
current for approximately 2 hours. 
2.10 Ponceau staining of proteins 
To estimate the efficiency of protein transfer after blotting, the membrane was stained 
with Ponceau-S. This stain is reversible and produces pink bands on a light background. 
The nitrocellulose membrane was washed with Millipore water for 1 minute, incubated in 
Ponceau-S solution for 2-3 minutes with constant shaking at room temperature. 
Subsequently the membrane was destained by washing in demineralized water to the 
desired contrast. Finally it was documented by a digital camera. To remove the stain 
completely, the membrane was washed again with TBST (1x TBS plus 0.1 % (vol/vol) 
Tween 20) under constant shaking. 
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2.11 Immunodetection of proteins 
Solutions 
10x Tris-buffered saline (TBS) 
Tris/HCl (pH 7.4)   100 mM 
NaCl     1.6 M 
 
TBS Tween (TBST) 
1x TBS 
0.1 % (vol/vol) Tween 20 
 
Blocking-buffer and antibody-dilution buffer 
5 % (wt/vol) BSA in 1x TBST (BSA)  
 
Primary Antibodies 
 
Antibody      Dilution   Dil.buffer 
Cx43 (Mouse IgG, polyclonal)   1:1000   TBST+BSA 
PhosphoCx43 Ser368 (Rabbit IgG, polyclonal) 1:1000   TBST+BSA 
Cx37 (Mouse IgG, polyclonal)   1:1000   TBST+BSA 
Cx40 (Rabbit IgG, polyclonal)   1:1000   TBST+BSA 
Tubulin (Rabbit IgG, monoclonal)   1:2000   TBST+BSA 
Vinculin (Clone hVIN-1, mouse IgG)  1:2000   TBST+BSA 
 
Secondary antibodies, horseradish peroxidase (HRP)-labeled 
Antibody     Dilution   Dilution buffer 
Anti-mouse IgG    1:1000   BSA 
Anti-Rabbit IgG    1:1000   BSA 
 
Procedure. After a brief washing with Millipore water and TBST, the membrane was 
blocked with 5% (wt/vol) BSA in TBST for 1 hour at room temperature. After blocking, 
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the membrane was incubated with primary antibody overnight at 4 °C. The membrane 
was then washed with TBST 3-4 times for 8-10 minutes each at room temperature and 
incubated with secondary antibody for 45 min at room temperature. After repeated 
washing with TBST 3-4 times for 10-15 minutes (each) the membrane was then 
incubated with enhanced chemiluminescence (ECL) solution and the luminescence was 
detected and recorded with Bio-Rad Quantity One gel documentation system and 
ChemiDoc imaging system. 
 
2.12 Immunocytochemistry 
Endothelial monolayers on glass cover slips were washed with 1X PBS and fixed with 4 
% (wt/vol) paraformaldehyde at 37 °C for 20 min, followed by permeabilization with 0.1 
% (wt/vol) Triton X-100 at 37 °C for 20 min. Cells were then washed 3-4 times with 1X 
PBS and blocked with 5 % (wt/vol) bovine serum albumin and 5 % (wt/vol) cold water 
fish skin gelatin for 1 h to prevent non-specific binding. Samples were then probed with 
primary antibody (1:500 dilution) overnight at 4 °C, followed by thorough washing in 1X 
PBS. Secondary antibodies tagged with Alexa fluor 488/ Alexa fluor 633 were used in a 
dilution of 1: 250 – 1:500 for 1 h at room temperature. The samples were then washed 
3-4 times with 1X PBS and mounted with buffered glycerol. Immunoreactivity was 
visualized and analyzed by confocal microscopy with a Carl Zeiss LSM 510. 
2.13 Statistical analysis 
 
Data are given as means ± S.D. of 3-5 experiments using independent cell 
preparations. The comparison of means between groups was performed by one-way 
analysis of variance (ANOVA) followed by a Student-Newman-Keuls post-hoc test. 
Changes in parameters within the same group were assessed by multiple ANOVA 
analysis. Probability (P) values of less than 0.05 were considered as significantly 
different (P< 0.05). 
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3 RESULTS 
3.1 Effect of reoxygenation on ATP release from endothelial cells 
Previously it has been shown that ATP, either exogenously applied or 
spontaneously released from coronary endothelial cells during reperfusion, protects 
against reperfusion-induced intercellular gap formation (Gündüz et al., 2006). Pilot 
experiments were performed to prove whether ATP is released in a similar way under 
the experimental conditions applied in the present study. Accordingly, cultured 
endothelial cells from porcine aorta were exposed to 40 min of hypoxia (Po2 < 10 mmHg) 
followed by reoxygenation (Po2= 140 mmHg). Control cells were exposed to normoxia 
for the same period of time. Supernatants of cell cultures were collected at indicated 
time points. ATP concentration of the supernantant was found to be increased after 5 
min of reoxygenation with a maximum at 15 min (Fig 1), whereas, no change in the ATP 
concentration was observed during normoxic and hypoxic conditions (data not shown). 
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Figure 1: Effect of reoxygenation on ATP release from porcine aortic endothelial cells. 
Cells were exposed to hypoxia (Po2 < 10 mmHg) for 40 min followed by reoxygenation 
(Po2 = 140 mmHg). ATP concentration of the culture supernatant was determined during 
reoxygenation at indicated time points. ATP concentrations are given as X-fold of the 
end-hypoxia value set to 1 (time point 0). Data are means ± SD of five separate 
experiments of four independent cell preparations. *P < 0.05 vs. time point 0 (end of 
hypoxia).  
 
 
As the increase in ATP concentrations in the supernatants of cells exposed to hypoxia 
and reoxygenation could be due to cell lysis, lactic acid dehydrogenase activity (LDH) 
was measured as surrogate parameter of cell membrane damage. As shown in Fig 2, 
LDH activity in the supernatant was below detection limit under all conditions tested, 
indicating that reoxygenation-induced ATP release from endothelial cells is not due to 
cell lysis.  
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Figure 2: The effect of hypoxia and reoxygenation on lactic acid dehydrogenase (LDH) 
activity in the culture supernatant of endothelial cells. Endothelial cells were exposed to 
40 min of normoxia (N), or 40 min of hypoxia (H) followed by 15 min of reoxygenation 
(R). In a set of experiments cells were collected before start of hypoxia (Ctr). Cells lysed 
with Triton X-100 served as a positive control and the LDH activity was set to 100%. 
Data are means of 3 experiments of different cell preparations. *P < 0.05 vs. Triton X-
100 control.  
 
 
 
 
 
           Results 
 Page 22 
 
3.2 Effect of pannexin and connexin channel inhibitors on reoxygenation-
induced ATP release from endothelial cells 
Pannexin or connexin hemichannels have been shown to be involved in ATP release 
from endothelial cells (Locovei et al., 2006; Goodenough and Paul, 2003). To analyze 
whether reoxygenation-induced ATP release is mediated by pannexins or connexins, the 
effect of pharmacological inhibitors on reoxygenation-induced ATP release was tested. 
The inhibitors were added at the onset of hypoxia followed by reoxygenation and 
supernatants were analyzed at 15 min of reoxygenation. The involvement of pannexin 
was tested by use of probenecid, known to inhibit the opening of pannexin channels 
(Silverman et al., 2008). This effect was verified by use of mefloquine which has been 
shown to inhibit pannexins at low concentrations (Dubyak, 2009; Iglesias et al., 2008). 
As shown in Fig 3, neither probenecid in a concentration of 0.01 to 1 mM nor mefloquine 
at concentrations of 0.01 to 1 µM influenced reoxygenation-induced ATP release. 
However, mefloquine concentrations above 10 µM as well as the pan-specific connexin 
inhibitors like 18-α glycyrrhetinic acid (GA) or flufenamic acid (FFA) (Goodenough and 
Paul, 2003) blocked reoxygenation-induced ATP release in a concentration dependent 
manner. Additionally, lanthanum chloride (La+3), which was shown to specifically inhibit 
the opening of connexin hemichannels but not Gj (Retamal et al., 2007), inhibited 
reoxygenation-induced ATP release in a concentration dependent manner at 100 and 
200 µM. 
Taken together, probenecid at any concentration as well as mefloquine at low 
concentration had no effect on reoxygenation-induced ATP release from endothelial 
cells speaking against an involvement of pannexins. However, high concentration of 
mefloquine as well as GA, FFA or La+3 were effective to block ATP release indicating 
that the reoxygenation-induced ATP release is connexin hemichannel dependent. 
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Figure 3: Effect of the pharmacological hemichannel inhibitors on reoxygenation-
induced ATP release of endothelial cells. Cultured endothelial cells were exposed to 40 
min of hypoxia (Po2 < 10 mmHg) followed by reoxygenation (Po2 = 140 mmHg). ATP 
release into the cell culture medium was determined 15 min after onset of 
reoxygenation, the time point of highest ATP release (see Fig. 1). Each pharmacological 
agent was added at the onset of hypoxia. (A) Probenecid, a pannexin-specific inhibitor; 
(B) mefloquine, an agent which blocks pannexin hemichannels at concentrations below 
10 µM and connexin hemichannels at concentrations above 10 µM; (C) 18-α 
glycyrrhetinic acid (GA) or flufenamic acid (FFA), both pan-specific inhibitors of 
connexins, added at maximum inhibitory concentration of 50 µM; and (D) lanthanum 
chloride (La3+.), a connexin hemichannel specific inhibitor. ATP concentrations of the 
culture supernatants are given as % to control (15 min of reoxygenation). The values of 
the control were set to 100%. Data are means ± SD of n=3 separate experiments of 
independent cell preparations. *P < 0.05 vs. control.  
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3.3 Effect of Cx43 silencing on reoxygenation-induced ATP release 
Effect of Cx43 silencing on Cx40 and Cx37 isoforms 
Early studies suggested a role for connexins in reoxygenation-induced ATP release in 
EC. To verify the data of the pharmacological approach of the preceeding paragraph, 
endothelial cells were transfected with siRNA specifically targeting Cx43. A significant 
reduction in the Cx43 protein content was observed after 24 h (upper panel of Fig. 4A), 
but not in cells treated with non-specific siRNA. Given that various connexins are 
transcriptionally co-regulated (Isakson et al., 2006; Wang, 2008), the protein content of 
other connexins such as Cx37 and Cx40 were also determined in Cx43 siRNA treated 
cells. As shown in the lower panel of Fig 4A, no alterations in Cx37 and Cx40 protein 
levels was detected in Cx43 siRNA silenced cells compared to untreated controls or 
cells transfected with non-specific siRNA. Similarly, immunoflourescence staining of 
Cx43, Cx40, and Cx37 in Cx43 downregulated cells resulted in similar observations as 
depicted in Fig 4B. 
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B 
 
 
 
 
 
 
 
 
 
Figure 4: Effect of Cx43 silencing on the content of Cx40 and Cx37.  
Endothelial cells were transfected with non-specific (NS) or Cx43 siRNA (Cx43) for 24 h 
under normoxic conditions, while non-transfected cells served as a control (Ctr). (A) 
Representative Western blots of Cx43, Cx40, and Cx37 in endothelial cells. Tubulin was 
used as respective loading control. (B) Immunoflourescence staining of Cx43, Cx40, and 
Cx37 in endothelial cells.  
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Effect of Cx43 silencing on reoxygenation-induced ATP release 
To check whether the induced ATP release in response to reoxygenation in endothelial 
cells is dependent on Cx43, the ATP concentrations in supernatants of endothelial cells, 
transfected with non-specific or specific siRNAs of non-transfected cells, were measured 
15 min after reoxygenation. As shown in Fig 5, reoxygenation-induced ATP release was 
abolished in Cx43 down regulated cells. Although siRNA silencing was performed under 
identical conditions, effectiveness of Cx43 downregulation in endothelial cells varied 
between experiments. To test whether there is a correlation between Cx43 content and 
ATP release, the ATP concentration of the culture supernatant was plotted against the 
corresponding Cx43 content of Cx43 downregulated and control endothelial cells. As 
shown in Fig 5, ATP release induced by reoxygenation closely correlates with the Cx43 
content in endothelial cells. 
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Figure 5: Reoxygenation-induced ATP release as function of the endothelial Cx43 
content.  
Endothelial cells were exposed to 40 min of hypoxia (Po2 < 10 mmHg) followed by 
reoxygenation (Po2 = 140 mmHg). ATP release into the cell culture medium of 
endothelial cells transfected with specific or non-specific Cx43 siRNA or of non-
transfected cells was determined 15 min after onset of reoxygenation, the time point of 
highest ATP release and Cx43 content of the corresponding cell monolayer was 
analysed and expressed as percent of untreated controls set to 100%. Data are means 
± SD of n = 3 separate experiments of independent cell preparations.  
 
 
3.4 Role of other connexins in reoxygenation-induced ATP release 
As shown before, reoxygenation-induced ATP is closely linked to the presence of Cx43 
in endothelial cells. Nevertheless, in addition to Cx43, which is one of the major 
connexin isoforms expressed in endothelial cells, Cx40 and Cx37 may also be involved 
in ATP release. To test this question, Cx43-downregulated endothelial cells were 
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additionally exposed to 18-α glycyrrhetinic acid (GA), a pan-specific connexin inhibitor, 
before onset of hypoxia. As shown in Fig 6, GA did not cause any additional reduction of 
the reoxygenation-induced ATP release in Cx43-downregulated endothelial cells, 
supporting the concept that the ATP release is mediated by Cx43. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Effect of 18-α glycyrrhetinic acid on reoxygenation-induced ATP release in 
Cx43 silenced cells. Endothelial cells, either transfected with non-specific (NS) or 
specific Cx43 (Cx43) siRNA as well as untreated control cells, were exposed to 40 min 
of hypoxia (Po2 < 10 mmHg) followed by reoxygenation (Po2 = 140 mmHg). ATP release 
into the cell culture medium was determined 15 min after onset of reoxygenation, the 
time point of highest ATP release. ATP release was measured in absence (white bars) 
or presence (grey bars) of the pan-specific connexin inhibitor 18-α glycyrrhetinic acid 
(GA; 50 µM) added at the onset of hypoxia. ATP concentrations of the culture 
supernatants are given as % to control (15 min of reoxygenation). The values of the 
control were set to 100 %. Data are means ± SD of n=3 separate experiments of 
independent cell preparations. *P < 0.05 vs. untreated control; n.s.: not significantly 
different.  
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3.5 Role of PKA in Cx43-dependent ATP release during reoxygenation 
As mentioned in the introduction, connexin function is regulated by a variety of kinases 
directly targeting connexins at specific phoshorylation sites. Activation of PKA is the 
most important factor for this signaling element, as it is the only kinase known to 
increase the Cx43 conductivity, transcription, and also channel opening (DeMello, 1988; 
Lampe and Lau, 2004; Matsumura et al., 2006). In order to investigate the role of 
cAMP/PKA pathway in the reoxygenation-induced ATP release via Cx43, cells were 
exposed to four chemically non-related PKA inhibitors blocking PKA by different 
mechanisms: H-89, KT5720, and two specific protein kinase inhibitor peptides PKI (6-
22-amide) or PKI (14-22-amide). As shown in Fig 7A, reoxygenation-induced ATP 
release was abolished in the presence of all four PKA inhibitors applied. These effects of 
PKA inhibitors are contrasted by the effect of two different direct PKA activators, i.e. Sp-
8-CPT-cAMPs (Sp-8) or 8-Br-cAMPs (8-Br), which both enhanced the release of ATP 
induced by reoxygenation (Fig 7B). The combined treatment with H-89 plus 8-Br-cAMPs 
abolished the 8-Br-cAMPs effect (Fig 7C), indicating that the reoxygenation-induced 
ATP release is mediated by PKA. 
 
 
 
 
 
 
 
 
 
 
 
 
           Results 
 Page 30 
 
A       B 
 
 
 
C 
 
 
 
 
 
 
 
 
 
Figure 7: Effect of pharmacological inhibition and activation of PKA on the 
reoxygenation-induced ATP release. Cultured endothelial cells were exposed to 40 min 
of hypoxia (Po2 < 10 mmHg) followed by reoxygenation (Po2 = 140 mmHg). ATP release 
into the cell culture medium was determined 15 min after the onset of reoxygenation, the 
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time point of highest ATP release. (A) Cells were exposed to PKA inhibitors H-89 (20 
µM), KT5720 (KT; 100 nM), or the specific PKA inhibitor peptides (PKI) 16-22 amide 
(100 nM) or 4-22 amide (5 µM), added at the onset of hypoxia. (B) Effect of the PKA 
activator 8-Br-cAMPs (8-Br; 1 µM) or Sp-8-CPT-cAMPs (Sp-8; 10 µM) on reoxygenation-
induced ATP release. The PKA activators were added at the onset of reoxygenation. (C) 
Effect of H-89, 8-Br-cAMPs, and H-89 plus 8-Br-cAMPs on reoxygenation-induced ATP 
release. ATP concentrations of the culture supernatants are given as % to control (15 
min of reoxygenation). The values of the control were set to 100%. Data are means ± 
SD of n=3 separate experiments of independent cell preparations. *P < 0.05 vs. control.  
 
 
To prove whether the cAMP/PKA effect on reoxygenation-induced ATP release is 
mediated by Cx43, cells transfected with Cx43 siRNA or non-specific control siRNA 
were exposed to hypoxia followed by reoxygenation. 8-Br-cAMPs was added at the 
onset of reoxygenation. As shown in Fig 8, downregulation of Cx43 in endothelial cells 
abolished the ATP release induced by reoxygenation. Under this condition 8-Br-cAMPs 
fails to increase the ATP release, whereas the cAMP analogue enhanced the 
reoxygenation-induced ATP release in non-transfected or control transfected cells. 
These findings suggest that the ATP release via Cx43 is modulated by the cAMP/PKA 
pathway in endothelial cells.  
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Figure 8: Effect of Cx43 silencing on reoxygenation-induced ATP release in presence of 
the PKA activator 8-Br-cAMPs. Endothelial cells, transfected with non-specific (NS) or 
specific Cx43 (Cx43) siRNA as well as untreated control cells were exposed to 40 min of 
hypoxia (Po2 < 10 mmHg) followed by reoxygenation (Po2 = 140 mmHg). ATP release 
into the cell culture medium was determined 15 min after onset of reoxygenation, the 
time point of highest ATP release. Cells were exposed to the PKA activator 8-Br-cAMPs 
(8-Br; 1µM; grey bars), or vehicle control (white bars), added at the onset of 
reoxygenation, respectively. ATP concentrations of the culture supernatants are given 
as % of control (15 min of reoxygenation). The values of the control were set to 100%. 
Data are means ± SD of n=3 separate experiments of independent cell preparations. 
*P<0.05 vs. respective control. #P<0.05 vs. non-stimulated Cx43 siRNA transfected 
cells. 
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3.6 Effects of reoxygenation on Cx43 phosphorylation 
Gj function is regulated at multiple levels, including Cx43 expression, degradation, and 
phosphorylation (Duffy et al., 2004; Saffitz et al., 2000; Leithe et al., 2004). The opening 
propability of Cx43 hemichannels is regulated by phosphorylation of specific serine 
residues causing a functional change in connexon permeability (Bao et al., 2004). 
Therefore, the effect of hypoxia/reoxygenation on the phosphorylation state of Cx43 was 
examined by Western blot analysis. The antibody used reacts with Cx43 when it is 
phosphorylated at Ser 368. To test the effect of reoxygenation on Cx43 phosphorylation, 
endothelial cells were exposed to 40 min of hypoxia (Po2 < 10 mmHg) followed by 
reoxygenation (Po2 = 140 mmHg) and samples were collected at indicated time points. 
As shown by Westernblot analysis Cx43 migrates in three bands separated during gel 
electrophoresis (Fig 9 top; Cx43 total). The leading band, indicated as Po, predominantly 
represents the non-phosphorylated form of Cx43 (Solan and Lampe, 2009; Solan et al., 
2007), whereas the two preceding band, indicated as P1 and P2, mainly represent the 
phosphorylated froms of Cx43 (Musil and Goodenough, 1991). Accordingly, the anti-
phospho Cx43 antibody raised against serine 368 detects a band at P1/P2. (Fig 9 top; 
P~Cx43) which is slightly increased after 5 minutes with a further increase at 15 min of 
reoxygenation, a time point of maximum ATP release. In contrast, hypoxia alone did not 
cause an increase in Cx43 phosphorylation or ATP release. This coincidence indicates a 
causal relationship between Cx43 phosphorylation and ATP release. 
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Fig 9: Effect of hypoxia and reoxygenation on Cx43 phosphorylation at serine 368. 
Cultured endothelial cells were exposed to 40 min of hypoxia (Po2 < 10 mmHg) followed 
by reoxygenation (Po2 = 140 mmHg). Representative Western blot of phosphorylated 
Cx43 (P~Cx43) at Ser 368 (upper panel) in comparison to total Cx43 (lower panel) 
during hypoxia (0 and 40 min) and reoxygenation (10 and 15 min). P2, P1, and Po 
indicate high, low, and non-phosphorylated form of Cx43, respectively. Densitometric 
analysis of Western blots is shown below. P~Cx43 relative to Cx43 total is given as % of 
control (0 min) normalized to 100%. Data are means ± SD of n=3 separate experiments 
of independent cell preparations.*P < 0.05 vs. end of hypoxia (40 min value).  
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3.7 Role of PKA on Cx43 phosphorylation during reoxygenation 
Maneuver causing elevation of intracellular cAMP increase Cx43 phosphorylation 
(Darrow et al., 1995). Therefore it was tested whether those inhibitors or activators of 
cAMP/PKA pathway as studied in Section 3.5, not only modulated ATP release in 
endothelial cells but also were able to influence the phosphorylation of Cx43.  
The reoxygenation-induced Cx43 phosphorylation was further increased in the presence 
of PKA activator 8-Br-cAMPs, and this effect could be abolished by the addition of the 
PKA inhibitors H-89, KT5720 or 6-22-amide peptide (PKI) (Fig 10A), or a combination of 
H-89 and 8-Br-cAMPs (Fig 10B), indicating that Cx43 may play a role in reoxygenation-
induced ATP release modulated by PKA. 
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Fig 10: Effect of activators and inhibitors of PKA on reoxygenation-induced 
phosphorylation of Cx43. Cultured endothelial cells were exposed to 40 min of hypoxia 
(Po2 < 10 mmHg) followed by 15 min of reoxygenation (Po2 = 140 mmHg). 
Representative Western blot of phosphorylated Cx43 (P~Cx43) at serine 368 (upper 
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panel) in comparison to total Cx43 (lower panel) and the densitometric analysis is shown 
below, respectively. (A) Effect of PKA inhibitors H-89 (20 µM), KT5720 (KT; 100 nM) 
and the specific protein kinase inhibitor peptide (PKI) 6-22 amide (100 nM) during 15 
min of reoxygenation, and (B) effect of PKA inhibitor H-89, PKA activator 8-Br or H-89 
plus 8-Br during 15 min of reoxygenation on Cx43 phosphorylation is shown. (H) Cx43 
phosphorylation after 40 min of hypoxia or (Ctr) 15 min of reoxygenation. The values of 
40 min end of hypoxia (H) were set to 100 %. P~Cx43 relative to Cx43 total is given as 
% of control normalized to 100%. Data are means ± SD of n=3 separate experiments of 
independent cell preparations.*P < 0.05:  
 
 
3.8 Effect of connexin channel openers on reoxygenation-induced ATP release 
Connexin channel openers are substances which have the ability to enhance the open 
propability of connexin channels by stabilizing its phosphorylated form (Clarke et al., 
2009; Plotkin, 2002). Two connexin channel openers: anti-arrhythmic peptide 10 
(AAP10) and alendronate were used to test whether they can effect reoxygenation-
induced ATP release. Therefore, endothelial cells were exposed to hypoxia followed by 
reoxygenation and the connexin channel openers were added at the onset of 
reoxygenation. As shown in Fig 11, both connexin channel openers enhanced the ATP 
release during reoxygenation. Pretreatment of cells with Cx43 siRNA abolished the 
effect of AAP10 as well as alendronate on ATP release, strengthening the concept that 
connexin channel opening is associated with ATP release during reoxygenation.  
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Figure 11: Effect of AAP10 and alendronate on reoxygenation-induced ATP release. 
Cultured endothelial cells were exposed to 40 min of hypoxia (Po2 < 10 mmHg) followed 
by reoxygenation (Po2 = 140 mmHg). ATP release into the cell culture medium was 
determined 15 min after onset of reoxygenation, the time point of highest ATP release. 
Endothelial cells, transfected with non-specific (NS) or specific Cx43 (Cx43) siRNA as 
well as untreated control wells were exposed to AAP10 (10 µM) or alendronate (10 µM). 
Both agents were added at the onset of reoxygenation. ATP concentrations of the 
culture supernatants are given as % to control (15 min of reoxygenation). The values of 
the control were set to 100 %. Data are means ± SD of n=3 separate experiments of 
independent cell preparations. *P < 0.05 vs. control. n.s: not significantly different. 
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In the next step it was tested whether AAP10 enhances the reoxygenation-induced ATP 
release via the PKA pathway. For that reason, endothelial cells were pre-incubated with 
the PKA inhibitor H-89 prior to hypoxia. AAP10 was added at the onset of 
reoxygenation. As shown in Fig 12, H-89 abolished the reoxygenation-induced ATP 
release even in presence of AAP10 below control level, indicating that the enhanced 
ATP release induced by AAP10 is triggerd by PKA. 
 
 
 
 
 
 
 
 
 
 
Figure 12: Effect of the connexin channel opener AAP10 and the PKA inhibitor H-89 on 
reoxygenation-induced ATP release. Cultured endothelial cells were exposed to 40 min 
of hypoxia (Po2 < 10 mmHg) followed by reoxygenation (Po2 = 140 mmHg). ATP release 
into the cell culture medium was determined 15 min after onset of reoxygenation, the 
time point of highest ATP release. The PKA inhibitor H-89 (20 µM) was added at the 
onset of hypoxia and AAP10 (10 µM) at the onset of reoxygenation. ATP concentrations 
of the culture supernatants are given as % to control (15 min of reoxygenation). The 
values of the control were set to 100%. Data are means ± SD of n=3 separate 
experiments of independent cell preparations. *P<0.05 vs. control.  
 
 
 
Finally, it was tested whether AAP10 affects Cx43 phosphorylation. Addition of AAP10 at 
the onset of reoxygenation increased Cx43 phosphorylation. However, the same effect 
is abolished after pre-incubation with H-89 prior to reoxygenation even in the presence 
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of AAP10 (Fig 13). PKA inhibition by H-89 reduced the Cx43 phosphorylation indicating 
that during reoxygenation PKA cause a Cx43 phosphorylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 13: Effect of AAP10 and the PKA inhibitor H89 on reoxygenation-induced Cx43 
phosphorylation. Cultured endothelial cells were exposed to 40 min of hypoxia (Po2 < 10 
mmHg) followed by 15 min of reoxygenation (Po2 = 140 mmHg). Representative 
Western blots of phosphorylated Cx43 (P~Cx43) at Ser 368 (upper panel) in comparison 
to total Cx43 (lower panel). (H) Cx43 phosphorylation after 40 min of hypoxia or (Ctr) 15 
min of reoxygenation. H-89 (20 µM) was added at the onset of hypoxia, whereas AAP10 
(10 µM) at the onset of reoxygenation. A representative experiment of 3 is shown. The 
values of 40 min end of hypoxia (H) were set to 100%. P~Cx43 relative to Cx43 total is 
given as % of control set to 100 %. Data are means ± SD of n=3 separate experiments 
of independent cell preparations.*P < 0.05 vs. C.  
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4 DISCUSSION 
4.1 Main findings 
Protection of endothelial barrier function is inevitable for the recovery of the 
reperfused heart and I-R causes failure of the endothelial barrier. The consequences are 
myocardial edema and functional impairment of the myocardium (Mehlhorn et al., 2001). 
ATP has been proven to be a barrier protective agent due to its presence in the 
surrounding environment of EC (Gündüz et al., 2006). As shown by Schwiebert et al., 
(2002) the endothelium is the local source of ATP within the vascular wall. EC release 
ATP under basal conditions. Enhanced release of ATP from endothelial cells was 
observed in response to various stimuli including hypotonic challenge, calcium agonists, 
shear stress, thrombin, ATP itself, lipopolysaccharides, and conditions of I-R 
(Schwiebert et al., 2002; Pearson and Gordon, 1979; Bodin and Burnstock, 1998; 
Bergfeld and Forrester, 1992; Clemens and Forrester, 1981). It has been shown that 
extracellular ATP either exogenously applied or spontaneously released from the EC 
provides protection of endothelial barrier function against reperfusion injury (Gündüz et 
al., 2006).  
In the present study, the hypothesis was tested whether connexins are 
candidates mediating the release of ATP during reoxygenation. The major findings are: 
(1) Porcine aortic endothelial cells release ATP during reoxygenation in a Cx43-
dependent manner. (2) This reoxygenation-induced ATP release is dependent on Cx43 
but not on Cx40, Cx37, or pannexins, and (3) is triggerd by intracellular signal 
transduction mechanism involving the cAMP/PKA pathway. (4) The ATP release 
coincided with cAMP/PKA-dependent phosphorylation of Cx43 at Serine 368. (5) 
Connexin channel openers further enhanced the reoxygenation-induced ATP release 
and increased Cx43 phosphorylation in a PKA-dependent manner. 
4.2 Endothelial cells release ATP during reoxygenation via connexins 
In the present study, it has been demonstrated for the first time that ATP released 
during reoxygenation in porcine aortic endothelial cells is Cx43 dependent. This finding 
implicates a novel function of Cx43 beyond Gj communication in the regulation of 
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endothelial barrier function. A transient ATP release with the highest ATP concentration 
in the cell culture medium was observed 15 minutes after onset of reperfusion. 
Simultaneous determination of LDH activity in the cell culture medium revealed no 
detectable LDH activity, neither during hypoxia nor during reoxygenation, verifying that 
the increase in ATP concentration of the culture supernatants was not due to cell lysis. 
The findings of the present study are in accordance with previous data showing that 
Cx43 in the plasma membrane is a prerequisite for ATP release from activated PMNs 
(Eltzschig et al., 2006). Faigle et al. (2008) studied the molecular mechanisms of 
endothelial-dependent ATP release during hypoxia and suggested a functional role of 
Cx43 in endothelial ATP release. Another finding suggested that exposure to acute 
hypoosmotic stress or mechanical stimuli results in the release of intracellular ATP via 
connexin hemichannels in bovine corneal endothelial cells (Gomes et al., 2005). Similar 
findings are reported by Stout et al. (2002) and Leybaert et al. (2003) for astrocytes.  
Since there is extensive evidence that not only Cx hemichannels but also Panxs 
channels may be involved in the release of ATP (Locovei et al., 2006; Goodenough and 
Paul, 2003; Evans et al., 2006; Kang et al., 2008), a pharmacological approach was 
applied in the present study to identify the routes of ATP release in endothelial cells. The 
Panxs inhibitor probenicid did not affect the ATP release during reoxygenation, 
indicating that Panxs channels are not involved in this release process. Mefloquine, 
which is known to inhibit Panxs at concentration below 10 µM and Cx at concentrations 
above 10 µM (Dubyak, 2009; Iglesias et al., 2008), did not have any effect on 
reoxygenation-induced ATP release at low concentrations. On the contrary, at 
concentrations above 10 µM, mefloquine reduced the reoxygenation-induced ATP 
release. The data further support the concept that Cx, rather than Panxs, channels are 
involved. In line with these data the presence of 18-α glycyrrhetinic acid (GA, 50µM) or 
flufenamic acid (FFA, 50µM), two pan specific inhibitors of Gj and Cx hemichannels, 
abolished reoxygenation-induced ATP release. Similar results were obtained with 
lanthanum chloride, a more specific Cx hemichannels blocker (Retamal et al., 2007), 
strengthening the conclusion that ATP is released via Cx hemichannels. The data of the 
present study are in line with a report from Faigle et al (2008), who have studied the 
molecular mechanisms of ATP release from endothelial cells during hypoxia. The 
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authors found that this release was abolished by using pan-specific inhibitors of Gj. 
Furthermore, connexin-mediated ATP release does not occur in endothelial cells only. 
Clarke et al., (2009) showed that the ATP release from myocytes under ischemia was 
attenuated in the presence of the connexin channel inhibitor glycyrrhetinic acid, 
suggesting that ATP release in a connexin-dependent manner is a mechanism not only 
restricted to endothelial cells but rather ubiquitous for all cells of the cardiovascular 
system. 
4.3 Reoxygenation-induced ATP release is predominantly mediated via 
connexin 43  
Since pharmacological inhibitors are quite unspecific in their mode of action 
(Evans and Boitano, 2001), reoxygenation-induced ATP release was determined in cells 
in which the Cx43 content was reduced by Cx43 siRNA transfection. In Cx43 silenced 
cells, release of ATP closely correlated with the cellular Cx43 content, suggesting that 
reoxygenation-induced ATP release is mediated via Cx43 hemichannels. There is 
evidence that reduction in Cx43 expression may lead to co-regulation of the expression 
of many other proteins, e.g. connexins too. Wang et al., 2008 reported that 
downregulation of Cx43 by siRNA alters the expression profile of human aortic 
endothelial cells in culture. They showed that Cx43 downregulation caused an increase 
in mRNA levels of Cx37 and Cx40, whereas the protein level of both connexins did not 
change in that model. Moreover, Cx40-/- mice have been demonstrated to have 
decreased Cx37 and Cx43. (Isakson et al., 2006; Simon and McWorter, 2003). This and 
other findings that the expression of several other proteins is disturbed in hearts from 
Cx43 double kockout mice had led to the conclusion that the expression of connexins 
are coregulated (Iacobas et al., 2005). In contrast, the present study showed that Cx43 
silencing did not affect the expression of Cx37 and Cx40, indicating that the reduction of 
ATP release in Cx43 silenced cells is due to lack of Cx43, but not of Cx37 or Cx40. In 
line with that, exposure of Cx43-silenced endothelial cells to the pan-specific connexin 
inhibitor, glycyrrhetinic acid, did not cause a further reduction of the ATP release during 
reoxygenation, supporting the concept that ATP release from endothelial cells is 
mediated by Cx43. A similar mechanism has also been described by Eltzschig et al. 
(2006) for PMN. In an animal model of inducible Cx43-deficient mice they showed that 
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Cx43 expression correlate with ATP release from PMN. Furthermore, the study 
demonstrate liberation of nucleotides at sites of acute inflammation by PMN, and identify 
Cx43-dependent ATP release which later on control the adenosine-dependent 
endothelial function. 
4.4 Role of PKA in reoxygenation-induced ATP release  
It is well documented that maneuvers increasing cellular cAMP levels in 
endothelial cells protect against endothelial barrier dysfunction in reponse to 
proinflammatory mediators like histamine, thrombin, oxidants, and tumor necrosis factor 
(Baluk and McDonald, 1994; He and Curry, 1993; Ochoa et al., 1997; Patterson et al., 
1994; Sheldon et al., 1993). The protective effect of cAMP on endothelial barrier function 
has been studied in vitro and in intact organ models (Minnear et al., 1989; Ochoa et al., 
1997) and under I-R conditions (Adkins et al., 1992). The mechanism by which cAMP 
functions to regulate endothelial permeability is presumed to occur predominantly 
through activation of PKA and the cAMP-binding protein Epac (exchange protein directly 
activated by cAMP) leading to stabilization of the endothelial cytoskeleton as well as 
cell-cell and cell-matrix adhesion structures (Cullere et al., 2005; Sayner, 2011).  
Surprisingly, direct activation of PKA by two different cAMP analogue, Sp-8-CPT 
as well as 8-Br-cAMPs, enhanced the ATP release during reoxygenation. These effects 
were abolished by combined treatment of the endothelial cells with a PKA activator plus 
inhibitor, 8-Br-cAMPs plus H-89, indicating that reoxygenation-induced ATP release is 
PKA mediated. These data were verified by application of a chemically not related 
peptide PKA inhibitor, PKI. PKI is a more specific inhibitor of PKA than H-89 or KT5720, 
which unlike PKI, act on other protein kinases and the cytosolic Ca2+ level as well 
(Davies et al., 2000). PKI binds to the free catalytic subunit of PKA and prevents 
phosphorylation of PKA targets (Murray, 2008). Similar function of cAMP/PKA was 
reported in rabbit erythrocytes which results in stimulation of signaling pathways that 
culminate in ATP release, indicating that cAMP/PKA-mediated ATP release may be a 
ubiquitous mechanism in cells of the cardiovascular system (Adderley et al., 2010). 
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Depending on the cell type, there are several pathways by which ATP may be 
released, e.g. via ATP-binding cassette (ABC) proteins, vesicles, as well as Cx or Panxs 
hemichannels (Goodenough and Paul, 2003; D’hondt et al., 2009). Evidence for an 
involvement of Panxs in ATP release comes from erythrocytes (Sridharan et al., 2010). 
The authors show that erythrocytes, when exposed to hypoxia, release ATP via Panxs 
channels. On the basis of several studies, Cx channels have been proposed to mediate 
ATP release in endothelial cells (Goodenough and Paul, 2003; Faigle et al., 2008; 
Gomes et al., 2005). In the present study, the involvement of Cx43 in the ATP release 
during reoxygenation was tested considering that other Cx as 43, and Panxs, may be 
involved in this liberation process. As mentioned above, Cx inhibitors interfere with ATP 
release. In addition, there is a notable correlation between Cx expression and ATP 
release. The involvement of Cx43 in ATP release has also been tested in Cx43 silenced 
endothelial cells challenged by PKA activators to enhance ATP release at the onset of 
reperfusion. In these experiments reoxygenation-induced ATP release was abolished 
even in the presence of PKA activators, indicating the functional impact of Cx43 on 
reperfusion-induced ATP release. Thus, it was reasonable to infer that Cx provided the 
ATP release pathway in the form of Cx hemichannels in the non-junctional membrane.  
4.5 Phosphorylation of Cx43 during reoxygenation is regulated by cAMP/PKA 
pathway 
Cx hemichannel as well as Gj activity is regulated at multiple levels, including 
Cx43 expression, degradation, and phosphorylation (Duffy et al., 2004; Saffitz et al., 
2000; Leithe et al., 2004). From the literature it is known that hypoxia or ischemia effect 
phosphorylation state of Cx43 in cardiac cells (Beardslee et al., 2000; Turner et al., 
2004). As a result of this, change in the phosphorylation status of serine residues of 
Cx43 hemichannels ultimately leads to the functional change in connexon permeability 
(Bao et al., 2004).  
As identified by Western blot analysis, phosphorylation of Cx43 at Ser368 was 
increased during reoxygenation in endothelial cells. This phosphorylation can be 
enhanced when the cells were reperfused in presence of direct PKA activator, and 
blunted in presence of three chemically not related PKA inhibitors. The coincidence of 
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the alterations of Cx43 phosphorylation and Cx43-mediated ATP release induced under 
identical conditions strongly suggests a causal relationship between ATP liberation and 
Cx43 in endothelial cells. 
Until today, there are no data available on Cx43 phosphorylation during the 
reperfusion conditions. Up to eight serine residues on the carboxyl tail of Cx43 are 
known to be phosphorylated by different kinases (Solan et al., 2007), but their 
relationship to hemichannel gating remains unclear (Sáez et al., 2005). It is well known 
that serine368 (Ser368) is the PKC-dependent phosphorylation site of Cx43, whereas 
serine364 (Ser364) is targeted by PKA (Lampe et al., 2000; Ek-Vitorin et al., 2006; 
TenBroek et al., 2001). However, it has also been reported that PKC and PKA may 
phosphorylate common serine residues (Wecker et al. 2001). Moreover, Yogo et al. 
(2006) have found that PKA has no selectivity among the four serine residues Ser365, 
Ser368, Ser369, and Ser373, indicating that these four serine residues were actually 
target sites for PKA.  
4.6 Connexin channel opener enhances the reoxygenation-induced ATP release  
During inflammation, failure of endothelial barrier is induced by a plethora of 
mediators leading to the edema formation. On the other hand, mediators like ATP, which 
may induce opposing effects on barrier function, are also released from vascular cells in 
response to pathophysiological conditions (Bodin and Burnstock, 1998; Bergfeld and 
Forrester, 1992; Clemens and Forrester, 1981; Bodin and Burnstock, 2001). It has been 
shown that extracellular ATP protects the endothelial barrier against the injurious effect 
of an inflammatory mediators such as thrombin (Gündüz et al., 2003; Kolosova et al., 
2005; Härtel et al., 2007). In addition, it has been shown that ATP is released from 
endothelial cells during reperfusion and blunts reperfusion-induced barrier failure 
(Gündüz et al., 2006).  
The present study revealed that ATP is released from endothelial cells in 
response to reoxygenation via a Cx43-dependent mechanism and that this release can 
be enhanced by maneuver activating the PKA signaling pathway targeting Cx43 
phosphorylation in endothelial cells. These data not only provide a molecular basis of 
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ATP release, but also point to a therapeutic option to enhance the accumulation of ATP 
in the extracellular medium and its barrier protective effect. However, due to its 
ubiquitous presence in all cells and involvement in countless signaling mechanisms 
mediating conflicting cellular effects, activation of the cAMP/PKA pathway is a less 
promising strategy for endothelial protection.  
Recently, it has been shown that Cx function, in regard to Gj communication, can 
be enhanced by a group of substances known as Cx channel openers (Clarke et al., 
2009; Plotkin et al., 2002). Therefore, two pharmacological non-related Cx channel 
openers were tested in the present study and their effect on reoxygenation-induced ATP 
release as well as their influence on cAMP/PKA triggered regulatory signaling on Cx43 
was analyzed. 
Alendronate, a 250 Da synthetic molecule, belongs to the group of 
bisphosphonates. It is applied for the treatment of several bone diseases and shows 
anti-apoptotic effects on osteocytes and osteoblasts by opening Cx43 hemichannels 
(Plotkin et al. 1999). This unsuspected role of Cx43 in regulation of cell survival in 
response to alendronate elucidated a novel Cx function in addition to its well known role 
in Gj communication (Plotkin et al., 2008). 
The second Cx channel opener is the antiarrhythmic peptide AAP10 (Salameh 
and Dhein, 2005). This is a hexapeptide known to increase intercellular Gj 
communication (Kjølbye et al., 2003). A much more stable chemical analogue of the 
hexapeptide AAP10, ZP123, also promoted electrical coupling in ventricular myocytes 
and attenuated gap junctional closure in acidosis (Eloff et al., 2003; Haugan et al., 
2005). Besides preventing arrhythmias, both substances also showed reduced infarct 
size when applied during and after myocardial infarction (Haugan et al., 2006; Hennan et 
al., 2006) 
Application of both Cx channel openers at the onset of reoxygenation enhanced 
the ATP release. These effects of AAP10 and alendronate was abolished in Cx43 
downregulated cells, demonstrating that Cx43 hemichannel opening during 
reoxygenation is involved in the ATP release. The results obtained from this study are in 
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agreement with previous findings (Clarke et al., 2009; Stahlhut et al., 2006), showing a 
three-fold increase in the release of ATP from myocytes in the presence of AAP10. 
Based on the observation it seems likely that release of ATP from endothelial cells 
during reoxygenation could be further enhanced by Cx channel openers acting not only 
on endothelial cells but also on other cells of the cardiovascular system.  
AAP10 was shown to activate PKC in a G-protein dependent manner resulting in 
Cx43 phosphorylation and improvement of Gj conductance (Weng et al., 2002; Müller et 
al., 1997; Dhein et al., 2001). As shown in this study, endothelial cells release ATP 
during reoxygenation via Cx43 hemichannels mediated by PKA activation. This raised 
the question by which mechanism a Cx channel opener enhances the reoxygenation-
induced ATP release. It was shown previously that AAP10 enhances the metabolic 
coupling via Cx43 Gj through activation of PKC (Easton et al., 2009). Using a 
pharmacological as well as siRNA approach, it was demonstrated in the present study 
that the ATP release from endothelial cells in response to reoxygenation is triggered by 
a PKA-dependent pathway. For that reason, endothelial cells were pre-incubated with H-
89 prior to hypoxia and then AAP10 was added at the onset of reoxygenation. There 
was a tremendous decrease in release of ATP with H-89 plus AAP10 as compared to 
the controls, suggesting that enhanced ATP release by AAP10 via Cx43 is PKA 
dependent. In addition, Cx43 phosphorylation was increased when AAP10 was added 
alone during onset of reoxygenation. Accordingly, the AAP10 effect is abolished when 
cells are pre-incubated with H-89 prior to reoxygenation even in the presence of AAP10.  
 
So far, the data of the present study show for the first time that AAP10 can 
modulate Cx43 function in a PKA dependent manner. It enhances ATP release from 
endothelial cells using the same signaling pathway, which is already stimulated during 
onset of reoxygenation. Although, the detailed mechanism underlying these effects are 
not fully understood, maneuver targeting hemichannel opening may be a promising 
strategy to protect endothelial cells during reperfusion.  
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4.7 Conclusions 
The present study demonstrates that reoxygenation of hypoxic endothelial cells 
liberates ATP in a Cx43-dependent process. The involvement of other Cxs, namely 
Cx37 and Cx40 or Panxs was ruled out by using pharmacological and molecular 
approaches. Reoxygenation stimulated the cAMP/PKA signaling pathway which targets 
Cx43 at Ser368 triggering an ATP release via Cx43. This reoxygenation-induced ATP 
release can by enhanced by Cx channel openers which also target the cAMP/PKA 
pathway by an as yet unidentified mechanism. It is suggested that the increase of this 
selective and temporary opening of Cx43 hemichannels strengthens the protective effect 
on endothelial barrier function, thus keeping reperfusion injury at bay. 
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6 SUMMARY 
Reperfusion-injury impairs endothelial barrier function and may lead to edema 
formation, impeding recovery of the reperfused heart. Recently is has been shown that 
ATP, spontaneously released from endothelial cells (EC) during reperfusion protects the 
endothelial barrier against reperfusion-injury. The aim of the present study was to 
identify the mechanism of this spontanous ATP release during reoxygenation in 
endothelia cells. The central hypothesis is that EC release ATP via a connexin-mediated 
route. It is shown that macrovascular endothelial cells from porcine (PAEC) release ATP 
via Cx43 hemichannels at the onset of reperfusion. Determination of LDH activity in the 
culture medium rouled out that the increase in ATP is due to release from lysed cells. 
Pharmacological inhibitors of connexin function, i.e., mefloquine at concentrations above 
10 µM, 200 µM La3+, 50 µM 18-α glycyrrhetinic acid or 50 µM flufenamic acid reduced 
reperfusion-induced ATP release. In contrast, maneuvers, which inhibit pannexins, like 
probenecid at concentrations between 10 µM to 1 mM or mefloquine at concentrations 
below 10 µM, did not affect ATP under the same conditions, indicating that ATP release 
is mediated via connexins rather than pannexins. These results were confirmed by using 
a specific Cx43-siRNA transfection strategy. The addition of the connexin hemichannel 
openers i.e anti-arrythmic peptide 10 (AAP10, 10 µM) or alendronate (10 µM) 
significantly increased ATP-release compared to the reoxygenated control. 
Reoxygenation-induced ATP release was also enhanced when a specific PKA-activator 
like 8-BrcAMP (1 µM), and Sp8CPT (10 µM) was added with the onset of reperfusion, 
while H-89 (20 µM), KT-5720 (100 nM) as well as two specific protein kinase inhibitor 
peptides 6-22-amide (100 nM) or 14-22-amide (5 µM) abrogated the effect. In line with 
that, Cx43 phosphorylation was reduced by PKA inhibitors and increased by activators, 
indicating that PKA mediated signaling mechanisms are involved in Cx43-mediated ATP 
release under these conditions.  
Conclusion: The present study demonstrates that endothelial cells release ATP in a 
Cx43-dependent process during reoxygenation. Reoxygenation stimulated the 
cAMP/PKA signaling pathway which targets Cx43 at Ser 368 triggering the ATP release 
via Cx43. This reoxygenation-induced ATP release is enhanced by two chemically not 
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related connexin channel openers also targeting the cAMP/PKA pathway. Strengthening 
of this endogenous mechanism by direct activation of cAMP/PKA pathway and 
temporary opening of Cx43 hemichannels could represent a new therapeutic strategy to 
prevent acute endothelial barrier failure during reperfusion-injury. 
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7 ZUSAMMENFASSUNG 
Reperfusionschäden stören die endotheliale Schrankenfunktion und können zur 
Entstehung von Ödemen führen. Hierdurch wird die Regeneration des reperfundierten 
Herzen beeinträchtigt. Wie kürzlich gezeigt wurde, schützt ATP, das spontan von 
Endothelzellen (EC) während der Reperfusion abgegeben wird, die endotheliale 
Schranke vor Reperfusionsschäden. Das Ziel der vorliegenden Studie war es, den 
Mechanismus der spontanen ATP-Freisetzung in Endothelzellen zu untersuchen. 
Zentrale Hypothese war hierbei, dass Connexin 43 (Cx43) an der endothelialen ATP-
Freisetzung während der Reoxygenierung beteiligt sind. Es wurde beobachtet, dass die 
ATP Freisetzung in makrovaskulären EC des Schweines zu Beginn der Reperfusion 
Cx43-abhängig ist. Messungen der LDH-Aktivität ergaben, dass dieser Anstieg der ATP-
Konzentration nicht auf Zelllyse zurückzuführen ist. Um den Mechanismus der ATP-
Freisetzung zu untersuchen, wurden EC einerseits mit den selektiven Pannexin- und 
Connexininhibitoren wie Mefloquine (10µM) und Lanthan-(III)-chlorid (200µM), sowie 
andererseits mit den panspezifischen Inhibitoren wie 18α-Glycyrrhetinic acid (50 µM) 
oder Flufenamic acid (50 µM) vorinkubiert. Dies führte zu einer Reduktion der durch 
Reperfusion verursachten ATP-Freisetzung. Wurde dagegen Pannexin mittels 
Probenecid in einer Konzentration zwischen 1µM und 10µM, oder Mefloquine in einer 
Konzentration kleiner als 10µM unter sonst gleichen Bedingungen gehemmt, führte dies 
nicht zu einer Reduktion der ATP-Freisetzung. Dies ist ein Hinweis darauf, dass die 
ATP-Freisetzung eher durch Connexin als durch Pannexin erfolgt. 
Diese Ergebnisse konnten durch eine spezifische Cx43-siRNA-Transfektionsstrategie 
bestätigt werden. Der Zusatz des anti-arrythmischem Peptids 10 (AAP10; 10µM) oder 
Alendronat (10µM), die Connexinkanäle öffnen, führte zu einer signifikanten Steigerung 
der ATP-Freisetzung im Vergleich zur reoxygenierten Kontrolle. Die durch 
Reoxygenierung induzierte ATP-Freisetzung wurde ebenfalls verstärkt, wenn 
spezifische Aktivatoren der PKA, wie 8-BrcAMP (1 µM), Sp8CPT (10 µM) und 6Bnz (10 
µM) zu Beginn der Reperfusion zugesetzt wurden. Dagegen trat dieser Effekt durch die 
Gabe von H-89 (20 µM), bzw. KT-5720 (100 nM) sowie das PKA-inhibierende Peptid 6-
22-amide (100 nM) oder 14-22-amide (5 µM) nicht auf. Gleichzeitig dazu bewirken PKA-
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Inhibitoren eine Abnahme der Connexin43-Phosphorylierung, während PKA-Aktivatoren 
diese verstärken, Das deutet darauf hin, dass PKA-vermittelte 
Signaltransduktionsmechanismen an der Cx43-vermittelten ATP-Freisetzung beteiligt 
sind. 
Schlussfolgerung: Die Ergebnisse der vorliegenden Studie zeigen, dass 
Schweineendothelzellen während der Reoxygenierung ATP mittels Cx43 freisetzen. Die 
Reoxygenierung stimuliert auch den cAMP/PKA-Signalweg, wobei der Angriffspunkt der 
Phosphorylierung das Serin an Position 368 von Connexin 43 ist. Durch Veränderungen 
an dieser Stelle wird die ATP-Freisetzung gesteuert. Die durch Reoxygenation 
verursachte ATP-Freisetzung wird durch zwei chemisch nicht verwandte Connexin-
Kanalöffner verstärkt, welche beide auf den cAMP/PKA-Signalweg einwirken. Eine 
Verstärkung dieses endogenen Mechanismus durch direkte Aktivierung des cAMP/PKA-
Signalweges und damit eine zeitlich begrenzte Öffnung des Connexin-Kanals könnte 
eine neue therapeutische Strategie sein, die akute endotheliale Schrankenstörung 
während der Reperfusion zu verhindern. 
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9 APPENDIX 
9.1 Chemicals and consumables 
6-amino hexanoic acid    Merck, Darmstadt, Germany 
Acrylamide solution (40%; wt/vol)  Amersham Pharmacia, UK 
Acrylamide      Carl Roth, Karlsruhe, Germany 
Ammonium persulfate    SERVA, Heidelberg, Germany 
Ammonium sulfate     Merck, Darmstadt, Germany 
ATP       Roche, Mannheim, Germany 
Benzonase®      Merck, Darmstadt, Germany 
Bisacrylamide solution (2%; wt/vol)  Amersham Pharmacia, UK 
Bisacrylamide     Carl Roth, Karlsruhe, Germany 
Bovine serum albumin    Sigma-Aldrich, Steinheim, Germany 
Bromophenol blue     Sigma-Aldrich, Steinheim, Germany 
Calcium chloride     Merck, Darmstadt, Germany 
Culture dishes     BD, Heidelberg, Germany 
Diethyl ether      Merck, Darmstadt, Germany 
Dimethyl sulfoxide     Sigma-Aldrich, Steinheim, Germany 
Di-sodium hydrogen phosphate   Carl Roth, Karlsruhe, Germany 
Dithiothreitol      Amersham Pharmacia, UK 
EDTA      Carl Roth Karlsruhe, Germany 
EGTA      Boehringer, Mannheim 
Endothelial cell basal medium® kit  PromoCell, Heidelberg, Germany 
Endothelial cell growth supplement  PromoCell, Heidelberg, Germany 
Eppendorf tubes (0.5, 1.5, 2 ml)   Eppendorf, Hamburg, Germany 
Falcon tubes (50 ml, 12 ml)   BD, Heidelberg, Germany 
FCS       PAA, Pasching, Austria 
Filter papers      Biotech-Fischer, Reiskirchen, Germany 
Glass cover slips     Menzel, Braunschweig, Germany 
Glycerol (100%)     Sigma-Aldrich, Steinheim, Germany 
Glycerol (87%)     Amersham Pharmacia, UK 
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Glycine      Carl Roth, Karlsruhe, Germany 
HBSS      PAA, Pasching, Austria 
hEGF       PromoCell, Heidelberg, Germany 
HEPES      Sigma-Aldrich, Steinheim, Germany 
LDH release Kit    Cyto-Tox One, Promega, Mannheim, Germany 
Magnesium chloride    Fluka, Switzerland 
Magnesium sulfate     Merck, Darmstadt, Germany 
Manganese chloride    Merck, Darmstadt, Germany 
-mercaptoethanol     Merck, Darmstadt, Germany 
Methanol      Merck, Darmstadt, Germany 
Millipore water     Millipore, Eschborn, Germany 
Molecular weight marker    Sigma-Aldrich, Steinheim, Germany 
Nitrocellulose membrane    Schleicher und Schuell, Dassel, Germany 
Nonidet P-40     Sigma-Aldrich, Steinheim, Germany 
Penicillin/streptomycin    Gibco BRL, Eggenstein, Germany 
Phosphorylase-b     Sigma-Aldrich, Steinheim, Germany 
Phosphorylase-kinase    Sigma-Aldrich, Steinheim, Germany 
Pipette tips      Eppendorf, Hamburg, Germany 
Pipettes      Eppendorf, Hamburg, Germany 
PKI      Calbiochem, Bad Soden, Germany 
PMSF      Sigma-Aldrich, Steinheim, Germany 
Ponceau S solution     SERVA, Heidelberg, Germany 
Potassium chloride     Merck, Darmstadt, Germany 
Potassium dihydrogen phosphate  Merck, Darmstadt, Germany 
Rubber policeman     BD, Heidelberg, Germany 
Scalpal (disposble)     Feather, Japan 
See Blue® (pre-stained marker)   Invitrogen GmbH, Karlsruhe, Germany 
Sodium azide     Merck, Darmstadt, Germany 
Sodium bicarbonate    Carl Roth, Karlsruhe, Germany 
Sodium chloride     Carl Roth, Karlsruhe, Germany 
Sodium di-hydrogen phosphate   Carl Roth, Karlsruhe, Germany 
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Sodium dodecyl sulfate    SERVA, Heidelberg, Germany 
Sodium fluoride     Sigma-Aldrich, Steinheim, Germany 
Sodium hydroxide     Carl Roth, Karlsruhe, Germany 
Sodium orthovanadate    Sigma-Aldrich, Steinheim, Germany 
Sodium thioglycolate    Sigma-Aldrich, Steinheim, Germany 
Sterile filters (0.22 μm)    Sartorius, Goettingen, Germany 
Sterile pipettes     BD, Heidelberg, Germany 
Sucrose      Sigma-Aldrich, Steinheim, Germany 
Super signal-west® (ECL solution)  Pierce biotech, Bonn, Germany 
Syringes (20 ml, 2 ml)    BD, Heidelberg, Germany 
TEMED      Sigma-Aldrich, Steinheim, Germany 
Transwell® membrane filters   Corning, NY, USA 
Tricholoroacetic acid    Merck, Darmstadt, Germany 
Tris base      Carl Roth, Karlsruhe, Germany 
Tritone X-100     SERVA, Heidelberg, Germany 
Trypsin-EDTA     Gibco-BRL, Eggenstein, Germany 
Tween 20      Amersham Pharmacia, UK 
Whatman® 3 MM filter paper   Millipore, Eschborn, Germany 
 
9.2 Pharmacalogical inhibitors and activators 
 
4-22 amide     Biolog, Bremen, Germany 
16-22 amide     Biolog, Bremen, Germany 
18-α Glycyrrhetinic acid   Sigma-Aldrich, Taufkirchen, Germany 
8-Br-cAMP     Biolog, Bremen, Germany 
AAP10     Biotrend, Köln, Germany 
Alendronate     Merck Bioscience, BadSoden, Germany 
Flufenamic acid    Sigma-Aldrich, Taufkirchen, Germany 
H-89      Biolog, Bremen, Germany 
KT5720     Merck Bioscience, BadSoden, Germany 
Lanthanum chloride    Sigma-Aldrich, Taufkirchen, Germany 
Mefloquine     Sigma-Aldrich, Taufkirchen, Germany  
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Probenecid     Sigma-Aldrich, Taufkirchen, Germany 
Sp-8-CPT     Biolog, Bremen, Germany 
 
9.3 Antibodies 
 
Primary antibodies 
Anti Cx43 (Mouse IgG, polyclonal)   BD Bioscience, Heidelberg, 
        Germany 
Anti PhosphoCx43 Ser368 (Rabbit IgG, polyclonal) Cell Signaling Technology, USA 
Anti Cx37 (Mouse IgG, polyclonal)   Biotrend, Köln, Germany 
Anti Cx40 (Rabbit IgG, polyclonal)   Biotrend, Köln, Germany 
Anti Tubulin (Rabbit IgG, monolclonal)   Merck Bioscience, BadSoden, 
        Germany 
Anti Vinculin (Clone hVIN-1, mouse IgG,   Sigma-Aldrich, Taufkirchen,  
  Germany 
 
Secondary antibodies 
Anti-mouse IgG HRP-conjugated     Amersham, Freiburg  
Anti-rabbit IgG HRP-conjugated     Amersham, Freiburg  
Anti-rabbit IgG Alexa 633-conjugated    Invitrogen, Karlsruhe  
Anti-mouse IgG Alexa 488-conjugated    Invitrogen, Karlsruhe 
 
9.4 siRNA transfection 
 
Cx43 siRNA     Eurogentec, Köln, Germany 
Control siRNA    Eurogentec, Köln, Germany 
JetSI Endo     Peqlab Biotechnology, Erlangen, Germany 
 
9.5 Laboratory instruments 
 
ATP Luminometer    Turner Designs Instruments, Sunnyvale, CA 
Beckman Allegra 64R centrifuge   Beckman Coulter, USA 
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Blotting chambers     Biotech-Fischer, Reiskirchen, Germany 
Electrophoresis apparatus    Biometra, Goettingen, Germany 
Gel documentation system   Quantity One series, Bio-Rad, Munich, 
 Germany 
Glass ware      Schott, Mainz, Germany 
Hamilton syringe     Hamilton, Bonaduz, Switzerland 
Incubators      Heraeus, Hanau, Germany 
Laminar flow hood     Heraeus, Hanau, Germany 
Tri-Carb 1600 TR liquid scintillation 
counter      Packard Instrument Company, CT, USA 
Magnet stirrer     Jahnke und Kunkel, Staufen, Germany 
Magnetic rack     DYNAL, Oslo, Norway 
Neubauer chamber     Superior, Marienfeld, Germany 
Phase contrast microscope   Olympus, Japan 
pH-Meter      WTW-Weinheim, Germany 
Photometer      Carl Zeiss, Jena, Germany 
Power supply     Biometra, Goettingen, Germany 
Rocker      Biometra, Goettingen, Germany 
Table top (centrifuge)    Eppendorf, Hamburg, Germany 
Vortexer      Heidolph, Kelheim, Germany 
Water bath      Julabo, Seelbach, Germany 
Water demineralisation unit   Millipore, Eschborn, Germany 
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